C12Y 304/15001
Peptidyl-dipeptidase a
Official title: Peptidyl-dipeptidase A (3.4.15.1)
C12Y304/15001 (Peptidyl-dipeptidase a) appears on 37 US grants and 67 published applications in this corpus.
Search patents in C12Y- Granted patents
- 37
- Published applications
- 67
- Assignees
- 51
- Inventors
- 154
- Latest grant
- 27 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 1 |
| 2003 | 2 | 3 |
| 2004 | 0 | 1 |
| 2005 | 2 | 4 |
| 2006 | 3 | 2 |
| 2007 | 1 | 2 |
| 2008 | 1 | 8 |
| 2009 | 1 | 4 |
| 2010 | 0 | 2 |
| 2011 | 4 | 4 |
| 2012 | 2 | 2 |
| 2013 | 0 | 1 |
| 2014 | 2 | 2 |
| 2015 | 2 | 1 |
| 2016 | 3 | 4 |
| 2017 | 2 | 2 |
| 2018 | 1 | 0 |
| 2019 | 2 | 1 |
| 2020 | 1 | 0 |
| 2021 | 0 | 1 |
| 2022 | 1 | 5 |
| 2023 | 0 | 7 |
| 2024 | 2 | 6 |
| 2025 | 0 | 1 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Modified Trichoderma fungal strain for the production of an enzyme cocktail27 Jan 2026US 12,534,500 B2Centro Nacional De Pesquisa Em Energia E Materiais
- Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders13 Aug 2024US 12,059,454 B2The Trustees of the University of Pennsylvania
- Compositions and methods for treatment of SARS-COV-221 May 2024US 11,986,516 B2Phenom Pharmaceuticals, LLC
- Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders8 Feb 2022US 11,241,487 B2The Trustees of the University of Pennsylvania
- Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertensions, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders20 Oct 2020US 10,806,775 B2The Trustees of the University of Pennsylvania
- Angiotensinogen-modulating compositions and methods of use thereof20 Aug 2026US 2026/0242783 A1ADARx Pharmaceuticals, Inc.
- Angiotensinogen-modulating compositions and methods of use thereof6 Aug 2026US 2026/0224606 A1ADARx Pharmaceuticals, Inc.
- Method for preventing infection of a healthy person or a healthy animal with a virus that uses ace2 as a receptor, binding inhibitor and medical device2 Apr 2026US 2026/0091066 A1Dexon Pharmaceuticals Inc.
- Multivalent display on enveloped particles with human oligomerization domains18 Sep 2025US 2025/0288662 A1Achelois Biopharma, Inc.
- Full-length human ace2 mouse model susceptible to emerging coronaviruses26 Dec 2024US 2024/0423176 A1
Most cited
By later US patents
- Enzyme treatment of foodstuffs for Celiac Sprue47US 7,303,871 B2The Board of Trustees of the Leland Stanford Junior University · 2007
- Enzyme treatment of foodstuffs for celiac sprue26US 7,943,312 B2The Board of Trustees of the Leland Stanford Junior University · 2011
- Enzyme treatment of foodstuffs for celiac sprue24US 7,910,541 B2The Board of Trustees of the Leland Stanford Junior University · 2011
- Biochemically active agents for chemical catalysis and cell receptor activation23US 5,460,830 AThe Regents of the University of California · 1995
- Method of obtaining protein hydrolysates16US 6,036,983 ANovo Nordisk A/S · 2000